Cobra Biologics has recently been contracted to develop a second cell line for Alligator Bioscience AB. Alligator has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a historically documented master cell bank (CHO-S) and chemically defined media. This delivers a time saving cell line development and clone selection process suitable for GMP manufacture.

In May 2015, Cobra released details of its involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator’s Phase I trial in advanced solid tumors. Earlier this month, as a result of the company’s ‘exceptional achievements within the life-science industry,’ Alligator won the coveted SwedenBIO Award 2016.

“Cobra has been manufacturing protein therapeutics since 1995, and our maximum protein expression platform, maxXpress, has proven to be very popular to customers looking for both speed and quality. I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programs and would like to congratulate the team on their prestigious SwedenBIO Award,” said Peter Coleman, CEO Cobra Biologics.

“Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system. We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development program,” added Dr. Per Norlén, CEO, Alligator Bioscience.

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP-approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. For more information, visit www.cobrabio.com.

Alligator Bioscience discovers and develops innovative antibody-based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. For more information, visit www.alligatorbioscience.se.